뉴스벤징가
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
· 발표
기사 요약
AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…